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Preventing smoking and smokeless tobacco use among people is vital to curbing the epidemic of 
tobacco use.  Nowadays, tobacco use is one of the four major risk factors (unhealthy diet, 
tobacco use, alcohol consumption, and physical in-activities) of Non-Communicable Diseases; it 
kills nearly six million people per year.  Tobacco is the only legal consumer products that can 
harm everyone expose to it, and tobacco companies tremendously invest on tobacco advertising 
to absorb more smokers. 
This study provides first time local evidence about cost of smoking among ischemic heart 
disease, lung cancer, stroke and other cerebro-vascular disease, chronic obstructive pulmonary 
disease, and tuberculosis patients in five main national hospitals namely Kosomak hospital, 
Khmer-Russia Friendship hospital, Calmette hospital, and NGO Hope center in Cambodia. 
Despite health care cost shown in this study is potentially under-estimated, it shows insights on 
economic and psychological burden caused by cigarette on individuals, family and society.  
The findings suggest the program intervention to combat the tobacco epidemic in Cambodia, it 
is also useful for documenting the changes in cost of smoking for monitoring the 
implementation of different provisions of the tobacco control legislation and the relevant 
Articles of the WHO Framework Convention.  
Tobacco use is the single most preventable cause of disease and death in the world today.  A 
coordinated program intervention including mass media campaigns, price increase, 
comprehensive ban of tobacco product advertising, promotion and sponsorship, prominent 
pictorial health warning, and community-level changes protecting people from second hand 
smoke and norms are effective in reducing the initiation of tobacco use among youth.  However, 
many of these tobacco control programs remain underfunded, it is imperative that the tobacco 
control stakeholders continue investing in tobacco prevention and control.  An increasing in 
spending on sustained comprehensive tobacco control programs will results in reductions in 
youth and adult smoking rates and ultimately in health care cost. 
The Ministry of Health sincerely congratulates the National Center for Health Promotion, 
development partners and relevant stakeholder for successfully conducting this study.  
 
     Phnom Penh,…………………………….….., 2016 
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Smoking imposes significant health burden, leading to morbidity and mortality associated with 
many diseases, including lung cancer, cancers of the upper aero-digestive tract, chronic 
obstructive pulmonary disease (COPD), ischemic heart diseases, and stroke. As found elsewhere, 
smoking increases the direct health care costs that can be classified as inpatient costs, 
outpatient costs, and costs associated with self-treatment; it also imposes costs related to 
productivity losses from premature mortality and morbidity.  This study aimed to provide 
scientific evidence of the direct and indirect health-related costs attributable to active smoking 
to support the development and implementation of tobacco control policies in Cambodia. 
The study examined costs related to active smoking of tobacco for both male and female (age 30 
and over) from the society's perspective, including the health care costs and the productivity 
loss. 
However, it did not estimate the costs related to second-hand smoke, the opportunity cost of 
tobacco purchases (expenditure on tobacco products), the costs associated with the risk of fires, 
the health cost of using tobacco products that are not smoked (e.g. chewing tobacco), and 
expenditure on buying cigarettes.  The study focused on costs associated with hospital 
treatment of five health conditions 1)-Ischemic heart disease (IHD), 2)-Lung cancer, 3)-Stroke 
and other cerebro vascular diseases, 4)-Chronic Obstructive Pulmonary Disease (COPD), 5)-
Tuberculosis.  The cost of outpatient care was not included due to the lack of data.  
This is the first study investigating the costs of smoking in Cambodia and both primary and 
secondary data were collected for this research.  It followed three phases, the first phase 
explored the health care costs attributable to active tobacco use, and the second phase 
estimated the productivity loss due to missed days at work and premature deaths attributable 
to active smoking.  The third phase consisted of eight case studies of patients who suffered from 
one of the four health conditions (except tuberculosis), to explore their health care seeking 
behavior and to provide an input into the second phase that required an estimate of the 
number of days a patent and his/her caregiver spend not working due to the illness.  
 
The calculation cost of smoking in phase one followed four steps: 1)-Estimating the number of 
admissions from the selected hospitals, 2)-Calculating of the cost of treating the selected health 
conditions  based on consultations and data collected from selected hospitals, 3)-Estimating the 
smoking attributable fraction (SAF), based on the gender-specific relative risk (RR) for each 
disease category, and 4)-Calculating the total health care cost attributable to smoking for the 
selected  diseases.  
In phase two, the study estimated productivity loss due to mortality and morbidity related to 
active smoking.  We used the estimate of the annual number of deaths attributable to smoking 
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and the average number of life year lost per smoker to estimate mortality-related productivity 
cost using the human capital approach.  The human capital (or the labor productivity) is 
measured by GDP per capita and the annual rate of inflation is assumed to equal the rate of 
depreciation.  The calculation of the morbidity-related productivity cost is based on average 
daily income, the average number of days a patient and his/her caregiver spend not working 
due to the illness.   
Case studies (phase three) were conducted with patients suffering from Lung Cancer, Ischemic 
Heart Diseases, stroke and COPD.  Eight patients (7 men and one woman) were interviewed and 
their data recorded.  Each patient sought health care from multiple sources including private, 
government and oversea facilities.  The cases that were diagnosed and treated in private or 
oversea facilities were not registered in national statistic as a case of that particular disease.  
This means that many cases of tobacco related diseases and their treatment are not reported in 
the official government statistics.  The health care costs incurred by the patients in our case 
studies from combined providers were about double of costs estimated for a patient treated in a 
national hospital. 
There were 6, 801 cases of the four diseases (IHD, LC, Stroke, COPD) treated at National 
government health facilities in 2013.  Only few cases were treated at regional hospitals dues to 
their limited capacity.  There were 12, 896 cases of TB treated by all TB Centre in the whole 
country in 2003.   
The study found that the total health care cost (in US$) treating the five diseases attributable to 
smoking was US$ 34.5 million.  The productivity cost of premature mortality for those disease 
reached US$ 120.8 million and the productivity cost of morbidity was about US$ 7.3 million.  In 
total, the costs attributable to health damage due to smoking reached US$162.7 million.  These 
costs are underestimated due to following factors: 1)-Number of disease-specific cases is under-
reported, because many patients seek treatment at private health care facilities or oversea and 
we were not able to capture those cases. 2)-Many patients may not be able to afford the 
treatment cost at public or private facility2. 3)-Our study only covered 5 diagnoses, but there are 
many other diseases associated with smoking. 4)-We did not include costs associated with 
second-hand smoke, the costs associated with use of noncombustible tobacco, and the costs 
associated with fires caused by smoking.  Despite this underestimation, the costs we captured 
represent about 1.05% of Cambodia’s 2013 GDP3.  Our estimate is comparable to similar 
2 Health sector review report, MoH, 2014 
3 World Bank, Cambodia’s 2013 GDP was US$15.23 billion 
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estimates from Vietnam where the smoking-related health costs represent 1.17% of Vietnam’s 
2010 GDP4, from the US (1.40% of 2005 GDP) and from China5 (0.7% of 2008 GDP).  
The costs of treating tobacco related diseases and the associated productivity loss is nearly 12-
time higher than the tobacco domestic tax revenue (US$13,825,230) generated by General 
Department of Taxation (GDT) only in 2013. 
The results show that smoking imposes an enormous financial burden on Cambodia society in 
particular among the poor.  Raising awareness among policy makers about this significant 
negative impact of smoking on Cambodia economy will be critical to ensure the adoption of 
stronger tobacco control policies in Cambodia.  Raising awareness among the general 
population about the burden that tobacco use poses on their household financial security is also 
necessary to gain support on tobacco control program. Raising excise tobacco taxes has been 
proven to be the win-win approach to reduce tobacco consumption while raising government 
tax revenue.  
4 Hoang Anh et all, 2012 Health care cost attributed to smoking in Vietnam, 2012 
5 Lian Yang et all. Economic cost attributable to smoking in China: update and an 8-year comparison, 
2000-2008. Tobacco Control 2011;20:266-272 
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Health Cost Associated with Active Tobacco Use 
 
Introduction 
Smoking imposes an enormous economic burden on society.  It can lead to illness in both 
smokers and non-smokers exposed to second-hand smoke.  The resulting smoking-related 
illnesses lead to the need for healthcare services and result in costs incurred in obtaining them. 
Smoking causes people to lose time from their regular activities and results in premature 
deaths.  Understanding the economic burden of smoking both in terms of monetary costs and in 
terms of lost time and lives can be helpful for determining how to reduce the impact on society6. 
Although the tobacco industry claims it creates jobs and generates revenues that enhance local 
and national economics, the industry’s overriding contribution to any country is suffering, 
diseases, and deaths.  Tobacco use currently costs the world hundreds of billions of dollars each 
year7.  Smoker waste vast amount of money on their tobacco addition, illness, and ill health can 
trigger a slide into extreme poverty.  Tobacco kills one quarter of all smokers during their most 
productive years.  Family member must expend valuable time and scarce resources for caring 
for their sick and dying smoking relatives.  In United State of America, in the year 2005, the 
direct health care costs attributable to tobacco use were US$ 184.54 billion, which equal to 
1.40% of GDP and in China was US$4.29 billion (Mackay et al, 2006)8, which equal 0.19% of GDP. 
The total cost attributable to tobacco use in China in 2008 was 0.7% of GDP9. 
The costs of smoking have been conducted in a number of developed countries, including the 
United States (Rice and Hodgson et al., 1986; Miller and Zhang et al., 1998a; Miller and Ernst et 
al., 1999; CDC, 2002), Canada (Collishaw and Myers, 1984; Kaiserman,1997), Australia (Collins 
and Lapsley, 2008), and Germany (Neubauer and Welte et al, 2006). These estimates have 
proven to be exceedingly helpful for tobacco control efforts.  Far fewer studies of smoking-
related costs have been conducted in the developing world, though some research has been 
conducted, including studies in China (Jin et al., 1995, Sung et al., 2006), India (John et al., 2009), 
Vietnam (Ross et al., 2007), and South Africa (Yach et al., 1992).  The research in the developing 
countries has been limited by the availability of data and resources to conduct such analyses. 
In Cambodia, smoking prevalence among adult men remains high.  The National Adult Tobacco 
Survey of Cambodia 2011 conducted by the National Institute of Statistics, Ministry of Planning 
6Economics of Tobacco Toolkits: Assessment of the Economic Costs of Smoking, WHO, 2011 
7WHO report on the Global Tobacco Epidemic, 2008 
8Judith Mackay, Michael Eriksen, and Omar Shafey, the tobacco atlas, second edition, WHO, 2006. 
9 Lian Yang et all. Economic cost attributable to smoking in China: update and an 8-year comparison, 
2000-2008. Tobacco Control 2011;20:266-272 
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indicates that about 2 million Cambodian adults currently consume tobacco products, of whom 
1.4 million (42.5% of adult men and 3.5% of adult women) smoke cigarettes, and more than half 
a million (0.8% of adult men and 13.8% of adult women) chew tobacco in the form of a betel 
quid. According to the Global Youth Tobacco Survey (GYTS) 2003, 8.8% of youth currently use 
any tobacco product (Male = 11.4%, Female = 3.2%), while 5.5% currently smoke cigarettes 
(Male = 7.9%, Female = 1.0%).  The total annual cash expenditure on cigarettes (manufactured, 
and hand-rolled) by current adult smokers of Cambodia was US$ 101,789,000 in year 201110.  
To reduce tobacco consumption and to reduce burden related to tobacco related diseases, the 
government of Cambodia gradually imposes stronger tobacco control measures.  The Royal 
Government of Cambodia (RGC) ratified WHO Framework Convention on Tobacco Control 
(FCTC) on 15 November 2005. Consequently programs and activities were carried out to reduce 
consumption of tobacco use including establishing the high-level Inter-Ministerial Committee for 
Education and Reduction of Tobacco use (IMC) and the FCTC Secretariat11.  The government of 
Cambodia has implemented important articles of the FCTC that lead to the reduction of tobacco 
use, for example, article 8 to ensure smoke-free environment by encouraging government 
ministries and institution to adopt smoke-free regulations.  To date 16 government ministries in 
Cambodia has issued such regulation and ban in-door smoking in their institutions.  
The implementation of article 12 and 14 of the FCTC aims to increase awareness of public about 
the harm of active and passive exposure to tobacco smoke.  In 2009 and 2010 the government 
has issued sub-decree on health warning (health warning label must cover 30% of a cigarette 
pack) and ban advertisement, promotion and sponsorship of tobacco.  These two sub-decrees 
had come to effect in 2010 and 2011, respectively. 
The National Assembly and the Senate have ratified the tobacco control law in April 2015 and 
signed by the King in May 2015.  The law will allow for stronger measures to be implemented in 
support of the FCTC, which will likely result in further reduction of tobacco consumption in 
Cambodia.  At the same time, the IMC had proposed an increase of tobacco tax that will help to 
reduce the uptake of tobacco use among youth.  The preparatory work for developing these 
new tobacco control measures has been led by a working group combined of members from 
Ministry of Economic and Finance.  The working group is demanding rigorous local data and 
analyses of the costs and benefits related to the proposed regulations. One of the important 
inputs is the estimate of the costs of smoking to the society. 
However, the costs to treat tobacco related diseases within the existing health care system, and 
the burden this represents for individuals, families, and the government are not known in 
10National Adult tobacco Survey Cambodia (NATCS) 2011, National Institute of Statistic, Ministry of Planning 
11FCTC Secretariat is a technical team from relevant member of the IMC, its main role is to provide technical support 
to the IMC and to advocate the policy makers of the line ministry of support tobacco control program in Cambodia. 
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Cambodia.  This knowledge gap severally limits the arguments for stronger legislation and 
policies to control tobacco use in Cambodia.  
To address this shortcoming, the National Centre for Health Promotion of the Ministry of Health 
Cambodia and its partners conducted a research project to examine the costs of active smoking 
from the society perspective, including both the health care costs as well as the productivity 
loss. 
Health Insurance for every Cambodian has not yet existed, although there are small scale private 
health insurance but it covers only a small portion of the population.  The government of 
Cambodia subsidizes some diagnosis and treatment, but individuals and family have to be 
responsible for the main health care cost through out of pocket expenses12, and large number of 
Cambodia population fall under this category. Such cost accounted for 60% of total health care 
expenditure in 2014 (US$ 622 million out of a little more than US$ 1 billion)Error! Bookmark not defined.. 
Objectives: 
 
The research aims to generate evidence of society costs attributable to smoking. This evidence 
will be used to advocate for adoption and enforcement of tobacco control laws and policies 
related to increase of tobacco tax in Cambodia.  
The specific objectives of this study are: 
1. To generate an estimate of health care costs directly attributable to active smoking.  
2. To generate an estimate of productivity loss related to both morbidity and mortality 
attributable to active tobacco use.  
3. To increase awareness and knowledge among policy makers and the general public 
about the society costs attributable to active tobacco use in Cambodia.  
 
Conceptual and theoretical framework 
The cost of smoking composes of direct and indirect costs.  This study aims to calculate both of 
these components: the direct costs (i.e. health care cost for treating tobacco-related diseases) 
and the indirect costs (i.e. productivity loss due premature death and sickness).  The conceptual 




12 MoH’s Annual’s Health Financing Report, 2015 
15 
 
                                                          




Data and Methods 
 
The study examined costs related to active smoking of tobacco for both male and female (age 
30+) from the society's perspective, including the health care costs and the productivity loss. 
This research does not estimate the costs related to second-hand smoke, the opportunity cost 
of tobacco purchase (expenditure on tobacco products), and the cost of using tobacco products 
that are not smoked (e.g. chewing tobacco). 
In order to capture the majority of the costs, but still make the study manageable and within the 
budget, we focused on costs associated with five health conditions: 
1. Ischemic heart disease (IHD) 
2. Lung cancer 
3. Stroke and other cerebro-vascular diseases 
4. Chronic Obstructive Pulmonary Disease (COPD) 
5. Tuberculosis 





Productivity loss due 
to sick leave  
Formal user fees 
Other direct costs 
Income loss due to    
premature death  
  
Indirect costs 
Health costs of smoking 
User’s costs Provider’s costs 
Capital depreciations 
Recurrent costs 




Labor costs and drugs,    
medical supplies, 
diagnosis test Transportation costs 
Caregivers’ costs 
Informal fees and 
other direct costs  
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secondary data were collected for this research.  
Given the lack of readily available hospital data and limited understanding of health care seeking 
behavior among tobacco users, the research team conducted the study in three phases.  The 
first phase explored the health care costs attributable to active tobacco use, and the second 
phase estimated the productivity loss due to missed days at work and premature deaths 
attributable to active smoking. The third phase consisted of eight case studies of patients who 
suffered from one of the four health conditions (except tuberculosis), to explore their health 
care seeking behavior and to provide an input into the second phase that required an estimate 
of the number of days a patent and his/her caregiver spend not working due to the illness. 
Each phase of the research is described below: 
Phase 1: Estimating health care costs 
The first phase was to calculate health care costs attributable to active use of smoking tobacco. 
In doing so, there was a need for data such as the annual number of cases of each health 
condition in the entire country by gender, the average treatment cost for each health condition, 
the prevalence of ever smokers and the relative risk (RR) for each health condition.  The 
calculation of health care cost attributable to active smoking followed 5 steps: 
Step 1: Estimating the number of cases by gender per health condition per year 
The number of cases per each health condition per hospital was based on the 2013 hospital 
records. The gender specific data were obtained from five selected national hospitals in Phnom 
Penh, and regional hospitals in provinces.  The national hospitals, namely (1) Kosomak hospital, 
(2) Khmer-Russia Friendship hospital, (3) Calmette hospital, and (4) an NGO hospital (Hope 
Centre), whereas, the regional hospitals were from Chey ChumNeah hospital in Kandal province, 
Battambang hospital in Battambang province, and KampongCham hospital in KampongCham 
province.  These hospitals were selected due to the fact that these are the main health care 
facilities in the country that have the capacity to treat the above mentioned health conditions of 
interest.  The four national hospitals received the majority of cases being treated in Cambodia. 
Before collecting the hospital data, the research team convened a one-day workshop in 
February 2014 with health professionals who worked in the four selected national hospitals and 
the three regional hospitals.  The purpose of the workshop was to identify treatment standard 
that each hospital applied to treat the related health condition and to understand how cases of 
the four health conditions were recorded.  We found that there was no national standard 
procedure for diagnosis and treatment of IHD, Lung Cancer, Stroke & other cerebro vascular 
diseases, and COPD.  In fact, the diagnosis and treatment of these health conditions varied 
across the health facilities and ability of the patients to cover the diagnosis and treatment. 
Health professionals who attended the workshop were heads of hospitals' technical offices, 
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directors and health specialists for the four diseases.  In the workshop, health specialists 
discussed current practices to diagnose and treat each health condition and reached a 
consensus on the standard diagnosis and treatment procedures in each hospital.  In addition, 
the workshop participants discussed how each case was recorded, the most appropriate 
approach to collect number of cases from the hospitals and potential challenges regarding the 
data collection.  Following the workshop, the research team designed a survey tools to collect 
data on the number of cases being treated in each hospital and the costs of diagnosis, treatment 
and follow up of each disease included in the study.  
Before the commencement of data collection, research team of the NCHP visited each hospital 
and convened meetings with the Director or the Deputy-Director or and technical bureau of 
each hospital to establish a local research coordinator in each hospital.  The role of the local 
research coordinator, which composed of one or two persons, was to facilitate the data 
collection, communicate with the investigators from the NCHP and to collect data on the four 
diseases in the whole year 2013.  The research coordinator worked closely with a nurse in each 
specialized ward to review medical records and extract the data on the number of cases being 
treated in 2013.  The research coordinators also followed up with other wards in case of a 
referral to avoid duplication of cases recorded.   
 
To capture the cases that were not referred to the national hospitals in Phnom Penh, the 
research team also collected comparable data from three regional referral hospitals (3RHs) 
located in three different provinces using identical methodology.  However, only few cases of 
COPD and stroke were found in the provincial hospitals. 
Unlike the number of cases for IHD, Lung cancer, Stroke & other cerebro vascular diseases, and 
COPD, the number of cases for TB were taken from Report on Tuberculosis published by the 
Centre National Anti-Tuberculeux (CNAT), Ministry of Health, Cambodia with data for 2013.  The 
report provided the number of TB cases by age and gender. 
The research team attempted to cross-validate the hospital data using the Health Information 
System (HIS) working closely with the Department of Planning and Health Information (DPHI).  
However, the available data was not detailed enough to extract the number of cases for each 
health condition as the cases for the diseases of interest were lumped into the category of 
‘other’ diseases. 
Step 2: Estimating the cost of treating a typical case of each selected health condition 
The cost per a typical case includes the cost of diagnosis, the cost of in-patient treatment, and 
the cost of outpatient follow-up within a year (Annex 1).  The costs vary according to the 
facilities where the treatment is provided. For example, health facilities that have better 
facilities, equipment, and specialists could charge more for the diagnosis, treatment and follow-
up.  The cost of treatment at a government health care facility is partly subsidized while the cost 
of treatment in a private clinic covers all the costs and contributes to the profit. 
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To determine the costs of treatment of a typical case (excluding TB), the research team met with 
health specialist in-charge of each specialized ward and head of technical bureau to assess the 
estimated cost of each procedure for diagnosis and treatment of each tobacco related diseases.    
The NCHP also cross-validated the fees with the finance office of the each hospital to ensure 
that the fees for the standard treatment were correct.  The research team further consulted a 
costing report Complementary Package of Activities (CPA1, 2, 3) published by the Ministry of 
Health13 that contains estimates of treatment costs.  However, the report did not contain any of 
the costs associated with any diseases relevant for this study.  
In order to compare costs between the government hospitals and the private and non-profit 
hospitals, the research team included one non-for-profit hospital (HOPE Center), one medium 
size private hospital, the Sain Maries and one well-established private hospital with high quality 
of care (Royal Rattanak Hospital, a branched of a private hospital in Bangkok).  
After collecting the costs for all diagnoses, it became clear that only Calmette hospital is able to 
treat all diagnosis of interest, and the most comprehensively.  Therefore, the costs provided by 
Calmette became the standard for the treatment costs. Costs collected from the private hospital 
were similar to Calmette, but the private hospital's services were not as comprehensive as 
Calmette's services. In fact, private hospitals often sent patients to Calmette if the patient’s 
condition required advanced care. Alternatively, the private hospital (Royal Rattanak) would 
send patients to Bangkok Hospital.  Therefore, basing the treatment costs in Cambodia on the 
costs in the Calmette hospital is well justified. 
 
The costs of treating a typical TB case included the cost per case of inpatient and outpatient 
treatment as well as the cost per case for identifying patients.  These estimates were obtained 
from the study of K. Pichenda, et al. (2012) 14, and  the study of Rajendra P. Yadav, et al., 2014. 
 
Step 3: Estimating the smoking attributable fraction (SAF) 
The WHO’s proposed method15 was employed to estimate SAF for each disease category 
stratifying the data by sex. 
13Guidelines for complementary package of activity (CPA) of the referral hospital from 2006 to 2010, December 2006, 
ministry of health:  In Cambodia, at sub-national level, the health system classified into three packages; CPA1, CPA2 
and CPA3, according the capacity of the health facility, in which the CPA 3 is the highest level of health care which 
provide comprehensive care. 
14 K. Pichenda, K. Nakamura, A. Morita, M. Kizuki, K. Seino, T. Takano, Non-hospital DOT and early diagnosis of 
tuberculosis reduce costs while achieving treatment success. (2012) 
15World Health Organization Economics of Tobacco Toolkit.  Assessment of the Economic Costs of Smoking 
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Where RR is the relative risk for cause-specific mortality related to tobacco use, P is the 
prevalence of ever smokers (Table 2), (i) represents the specific diseases and (j) is sex.   
The study estimated SAF based on Relative Risk (RR) of four diseases based on the global 
standard of the CPS-II study (Table1).   
Table 1: Relative risk 
  Age groups CPS-II RRs16 
Diseases (ICD-10 codes)  Male Female 
Lung cancer (C33-C34) <70 yrs 21.3 12.5 
Chronic obstructive pulmonary 
disease (I27, J40-J44) 
<70 yrs 10.8 12.3 












Source: CPS-II RRs from 3 studies: 1) Ezzati M, Henley SJ, Thun MJ, Lopez AD (2005) Role of smoking 
in global and regional cardiovascular mortality. Circulation 112: 489–497; 2) Ezzati M, Henley SJ, 
Lopez AD, Thun MJ (2005) Role of smoking in global and regional cancer epidemiology: current patterns 
and data needs. Int J Cancer 116: 963–971; 3) Thun MJ, Apicella LF, Henley SJ (2000) Smoking vs other 
risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 284: 706–
712 
 
Given that the life expectancy in Cambodia is 70 and 75 for male and female, respectively17, we 
did not employ the RR for the age group70+. 
The RR estimate for TB disease ranges from 2.33 (95% CI, 1.97-2.75) to 2.66 (95% CI, 2.15-
3.28)18. The RR for TB is not gender specific. 
We assumed that the SAF of acquiring the disease is identical to SAF of the total costs of treating 
the disease.  This means that we assume that the cost of treatment of a particular disease is 
identical for smokers and non-smokers.  This assumption results in underestimation of the total 
costs, because it is often violated in studies outside Cambodia.  The data from Cambodia is 
currently not sufficient to uphold this claim. 
16Michael J. Thum 2010, Luis F. Apicella, S. Jane Henley. Smoking vs Other risk factors as the cause of smoking 
Attributable Death.  The authors calculated for 30% reduction of RRs 
17 World Health Organization, http://www.who.int/countries/khm/en/ retrieved on 13 July 2015 
18Michael N. Bates, PhD; Asheena Khalakdina, PhD; MadhukarPai, MD, PhD; Lisa Chang, MPH; Fernanda Lessa, MD, 




                                                          
The prevalence of ever smoker was based on the 2012 National Adult Tobacco Survey of 
Cambodia.  The ever-smoking prevalence was calculated by subtracting the percentage of never 
smokers from all Cambodian adults aged 15 and over.  (Table 2) 
Table 2: Ever smoker prevalence 
  Male Female All 
Never-smoker 55.60% 96.10% 77.8% 
All  100% 100% 100% 
Ever smokers 44.40% 3.90% 22.2% 
 
Step 4: Calculating the total health care cost for selected  diseases that are attributable to smoking 
We used results of Steps 1 – 3 to calculate the total health care costs attributable to active 
smoking for the selected heath conditions. 
One year health care costs (per disease) = cost per a typical case * number of cases in  
                                                                 one year * SAF 
Step 5: Estimating the full provider cost  
Diagnosis and treatment costs obtained from the Calmette hospital represent the costs of 
treatment, but do not cover the capital depreciation and the hospital fixed costs also referred to 
as recurrent costs.  
Despite multiple efforts, the research team was unable to obtain estimates of the depreciation 
and the recurrent costs.  Not including these costs would lead to the underestimation of the 
total costs.  To solve this problem, it is assumed that the health care cost structures in Cambodia 
resemble that of Vietnam where the rate of capital depreciation and recurrent costs was 54.7% 
of the total treatment cost based on a 2012 study19. 
Phase 2: Estimating the Productivity Loss 
The second phase of the study estimated the productivity loss due to mortality and morbidity 
related to active smoking as well as the productivity loss due to providing care for those with the 
selected health conditions. 
19 Hoang Anh Pham Thi, Thu Le Thi, Hana Ross, Quynh Anh Nguyen, Linh, Bui Ngoc. Direct and Indirect 
Costs of Smoking in Vietnam. Tobacco Control 2014; doi:10.1136/tobaccocontrol-2014-051821 
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Step 1: Estimating mortality-related productivity costs using human capital approach 
One possible approach to estimate the impact of smoking-related mortality on a country's 
economy is to employ smoking-attributable DALY estimates.  However, these estimates have 
been criticized due to their upward bias, which is particularly pronounced in countries with 
relatively low life expectancy such Cambodia.  An alternative approach employed in this study 
involves an estimate of the annual number of deaths attributable to smoking and the average 
number of life year lost per smoker.  The productivity is measured by GDP per capita and the 
annual rate of inflation is assumed to equal the depreciation rate.  
Mortality productivity cost = (average current smoker's year life lost*number of 
death/year)*GDP per capita 
The number of deaths attributable to tobacco was provided by the WHO (10,000 deaths per 
year) and the estimate of the number of life years lost by a smoker (12 years of life) came from 
the Surgeon General report, 2014.  The GDP per capita (1,007 USD) came from the World 
Bank20. 
Step 2: Estimating morbidity-related productivity cost 
The morbidity-related productivity cost for a patient with one of the health conditions is 
calculated as followed: 
Morbidity-related productivity cost= average income per day of a worker*(# of days in 
hospital+# of unproductive days at home)* # of cases in year 2013* 2*SAF  
The average income per day is based on the average salary of garment factory worker (USD 7per 
day), the estimate of the number of days spent in a hospital is based on data from Khmer_Russia 
Friendship Hospital and it varies by disease (Table 3).  Number of cases of each disease in one 
year (2013) is based on hospital records. Since each patient in Cambodia requires at least one 
caregiver (based on the information from the case studies), the costs per patient are multiplied 
by 2, and multiplied by smoking attributable fraction (SAF). 
Table 3: Average number of days a patient spent at hospital and at home for one time of treatment and 
care 
Disease  Average number of day of 
treatment in Hospital 
Average number of day of 
care at home 
 Lung cancer 10 days 10 months = 210 Days 
Ischemic heart disease  8 days  10 days 
Stroke, and other celebro-vascular 
diseases 
10 days 1 Year 
20http://data.worldbank.org/indicator/NY.GDP.PCAP.CD retrieved on 22 April 2015 
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Chronic Obstructive Pulmonary Disease 10 days 20 days 
Tuberculosis  21 days 
 
The total cost attributable to smoking is calculated by adding the health care costs and the costs 
associated with the productivity loss. 
Phase 3: Case studies 
The research team conducted eight case studies to explore the socio-demographic background, 
of patients to examine their health seeking behaviour from the disease onset until the time of 
the interview as well as costs associated with health care.  
 
The cases were selected from Calmette hospital and from Khmer-Russia Friendship hospital. 
Being smoker is a condition for being eligible to participate in the study.  The hospital provided 
list of patients who sought care from the hospital during the research period. The research team 
members contacted the patients, explained to them the purpose of the study and invited them 
to participate in it.  If the patient agreed to participate, researcher made an appointment for an 
interview.  The interview took place at patient’s residence or at hospital according to patient’s 
choice. 
 
On the interview day, a researcher reiterated the study objectives, outlined the risks and the 
benefits to participate in the research and seek consent to tape record the interview.  A 
structured interview took approximately 90 minutes and was based on an interview guide 
developed by the research team (see Annex 2) and the research advisor.  Each participant was 
contacted several weeks later for a follow-up interview in order to assess the progress of their 
disease and to clarify any concerns related to their health seeking behavior and their costs 
associated with health care.  
 
The total of eight cases was conducted including seven men and one woman.  The research 
originally aimed to have equal number of men and women, but because the smoking 
participation among women in Cambodia is extremely low (2.4% in 2014) and it was not possible 
to recruit sufficient number of women suffering from the diseases included in our study. 
Therefore, the research team proceeds with selection of more male cases. Summary of case 
characteristic is in Annex 2.  
 
Ethical Issues 
The study (quantitative and qualitative) has obtained an ethical approval from the National 
Ethics Committees on Health Research (NEC) on 20 March 2015. 
The participation in the study was voluntary. All study participants signed an informed consent 
to participate in the study.  The individual-level data collected during the study are kept 
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confidential and only research team had access to them in order to conduct the analyses.  In 
addition, the information provided by the hospital was approved by the management of the 
hospital to ensure its accuracy for research purpose. 
Following the completion of data collection and preliminary analysis, the NCHP convened the 
second workshop in March 2015, with an international research adviser, heads of hospital 
technical offices, directors, disease specialists and local research coordinators to present 
findings from the national and regional hospitals who provided their data to the research team. 
The purpose of this workshop was to validate the number of cases, the costs per diagnoses, and 
to discuss the data limitations. Participants at the workshop agreed that the number of cases 
and the costs per case were realistic and captured well the situation in Cambodia. 
Results 
This section presents findings on the direct health care costs, including depreciation costs as 
well as the productivity lost related to smoking. 
Phase 1: Health care costs 
There are five steps to estimate the health care costs of smoking.  
Step 1: Number of cases 
The participating hospitals and the CNAT provided the number of cases for the five diseases 
stratified by sex and age groups.  There were 19,697 cases (9,207among female) in Cambodia in 
2013. (Table 3)  
Table 4: Number of cases of each disease by sex and age in year 2013 
Diseases # of case (Male) # of case (Female) # of case (Total) 













Lung Cancer 61 153 214 55 138 193 407 
Ischemic Heart Disease  117 247      364 146 268 414 778 
Stroke and other cerebro-
vascular diseases 407 1,425 1,832 534 1,386 1,920 3,752 
COPD 430 556 986 392 486 878 1,864 
TB21 2529 4565 7094 1972 3830 5802 12896 
Grand Total 3,544 6,946 10,490 3,099 6,108 9,207 19,697 
 
21Report on Tuberculosis cases year 2013, Centre National Anti-Tuberculeux (CNAT), Ministry of Health, Cambodia 
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Step 2: Estimating treatment cost per one case of each health condition 
The costs per case were obtained from the Calmette hospital, because this hospital offers the 
most comprehensive data on the costs of various procedures required for a standard diagnosis 
and treatment. (Annex 1) 
The cost per case of Tuberculosis was based on the two studies conducted by Centre National 
Anti-Tuberculeux (CNAT).  The total costs of TB consist of the cost of inpatient treatment 
(US$1,900 per case), the cost of outpatient treatment (US$395 per case)22 and cost of 
identifying a patient (US$448.50)23.  The total cost of TB treatment was US$2,743.50 per case. 
The treatment costs vary by the disease with Ischemic Heart Disease (IHD) being the most 
expensive followed by Stroke.   
 

















Step 3: Estimating smoking attributable fraction (SAF) 
After obtaining the cost per case, the next step was to determine what percentage of these costs can be 
attributed to smoking.  The investigators estimated the SAFs based on the RR of each disease.  The RRs 
and the resulting SAFs are presented in Table 4 and 5  
22K. Pichenda, K. Nakamura, A. Morita, M. Kizuki, K. Seino, T. Takano,Non-hospital DOT and early diagnosis of 
tuberculosis reduce costs while achieving treatment success. (2012) 
23Rajendra P. Yadav, Nobuyuki Nishikiori, PeouSatha, Mao T. Eang, and YoelLubell, Cost-Effectiveness of a 
Tuberculosis Active Case Finding Program Targeting Household and Neighborhood Contacts in Cambodia, (2014) 
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Table 5: Relative Risk of the five diseases 
  Age groups CPS-II RRs24 
Diseases (ICD-10 codes)  Male Female 
Lung cancer (C33-C34) <70 yrs 21.3 12.5 
Chronic obstructive pulmonary 
disease (I27, J40-J44) 
<70 yrs 10.8 12.3 












The summary RR for TB infection N/A 1.73 
  
Table 6: Summary of the SAF of the five diseases 
Diseases Male Female 
30-45 years old 49-59 years old 30-45 years old 46+ years old 
IHD 66.70% 47.50% 4.70% 9.80% 
Lung  Cancer 90.00% 31.00% 
Stroke 39.00% 48.50% 4.40% 12.30% 
COPD 81.30% 30.60% 
TB 13.94% 
 
SAF of Ischemic Heart Diseases: 
 
SAF of Ischemic Heart Diseases for male age 30-45 years old 
P=0.444, and RR(M)=5.51, therefore 
SAF (M)=[0.444*(5.51-1)]/{[0.444*(5.51-1)]+1}*100=66.7% 
This means that 66.7% of the cost of IHD for male aged from 30 to 45 can be attributed to 
smoking. 
 
SAF of Ischemic Heart Diseases for male age 45-59 years old 
P=0.444, and RR(M)=3.04, therefore 
SAF (M)=[0.444*(3.04-1)]/{[0.444*(3.04-1)]+1}*100= 47.5% 
This means that 47.5% of cost of IHD for male aged 46 + can be attributed to smoking. 
 
SAF of Ischemic Heart Diseases for female aged 30-45 years old 
P=0.039, and RR(F)=2.26, therefore 
24Michael J. Thum 2010, Luis F. Apicella, S. Jane Henley. Smoking vs Other risk factors as the cause of smoking 
Attributable Death.  The authors calculated for 30% reduction of RRs 
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SAF(F)=[0.039*(2.26-1)]/{0.039*[(2.26-1)]+1}*100=4.70% 
This means that 4.7% of cost of IHD for female aged 30 to 45 can be attributed to smoking. 
 
SAF of Ischemic Heart Diseases for female aged 46+  years old 
P=0.039, and RR(F)=3.78, therefore 
SAF(F)=[0.039*(3.78-1)]/{0.039*[(3.78-1)]+1}*100=9.8% 
This means that 9.8% of cost of IHD for female aged 46+can be attributed to smoking. 
 
SAF of Lung Cancer 
SAF of Lung Cancer for male  
P=0.444, and RR(M)=21.3, therefore 
SAF (M)=[0.444*(21.3-1)]/{0.444*[(21.3-1)+1]}*100=90% 
This means that 90% of cost of lung cancer among male can be attributed to smoking 
 
SAF of Lung Cancer for female  
P=0.039, and RR(M)=12.5, therefore 
SAF(F)=[0.039*(12.5-1)]/{0.039*[(12.5-1)]+1}*100=31%. 
This means that 31% of cost of lung cancer among female can be attributed to smoking. 
 
SAF for Stroke 
 
SAF for male age 30-45 years old 
P=0.444, and RR(M)=2.44, therefore 
SAF (M)=[0.444*(2.44-1)]/{[0.444*(2.44-1)]+1}*100=39% 
This means that 39% of cost of stroke for male aged from 30 to 45 can be attributed to smoking. 
 
SAF for Stroke for male age 46+ years old 
P=0.444, and RR(M)=3.12, therefore 
SAF (M)=[0.444*(3.12-1)]/{[0.444*(3.12-1)]+1}*100= 48.5% 
This means that 48.5% of cost of stroke for male aged from 46 + can be attributed to smoking. 
 
SAF for Stroke for female aged 30-45 years old 
P=0.039, and RR(F)=2.18, therefore 
SAF(F)=[0.039*(2.18-1)]/{0.039*[(2.18-1)]+1}*100=4.4% 
This means that 4.4% of cost of stroke for female aged 30 to 45 can be attributed to smoking. 
 
SAF for Stroke for female aged 46+ years old 




This means that 12.3% of cost of stroke for female aged 46+can be attributed to smoking. 
 
SAF for COPD 
 
SAF for COPD for male 
P=0.444, and RR(M)=10.8, therefore 
SAF (M)=[0.444*(10.8-1)]/{0.444*[(10.8-1)+1]}*100=81.3% 
This means that 81.3% of cost of COPD for male can be attributed to smoking. 
 
SAF for COPD for female 
P=0.039, and RR(F)=12.3, therefore 
SAF(F)=[0.039*(12.3-1)]/{0.039*[(12.3-1)]+1}*100=30.6% 
This means that 30.6% of cost of COPD for female can be attributed to smoking. 
 
SAF for Tuberculosis (TB) 
 
P=0.222, and RR=1.7325, therefore 
SAF=[0.222*(1.73-1)]/{0.222*[(1.73-1)]+1}*100=13.94% 
This means that 13.94% of TB cost be attributed to smoking. 
 
Step 4: Calculating the total health care costs for selected  diseases that are attributable to smoking 
 
Ischemic Heart Diseases: US$1,658,608 
 
Male 30 to 45 years old 
Number of cases =117, cost per case=7,259, and SAF=0.667, therefore 
The cost of treatment of IHD attributable to smoking tobacco for male 30 to 45 years old 
=117*7,259*0.667=US$566,485 
 
Male 46+ years old 
Number of cases =247, cost per case=7,259, and SAF=0.475, therefore 
The cost of treatment of IHD attributable to smoking tobacco for male 46+ years 
old=247*7,259*0.475=US$851,662 
 
Female 30 to 45 years old 
25Michael N. Bates, PhD; AsheenaKhalakdina, PhD; MadhukarPai, MD, Ph; 
Lisa Chang, MPH; Fernanda Lessa, MD, MPH; Kirk R. Smith, PhD, Risk of Tuberculosis From Exposure 
to Tobacco Smoke, A Systematic Review and Meta-analysis, 2007 
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Number of cases =146, cost per case=7,259, and SAF=0.047, therefore 
 
The cost of treatment of IHD attributable to smoking tobacco for female 30 to 45 years old 
=146*7,259*0.047=US$49,811 
 
Female 46+ years old 
Number of cases =268, cost per case=7,259, and SAF=0.098, therefore 
The cost of treatment of IHD attributable to smoking tobacco for female 46+ years old 
=268*7,259*0.098=US$190,650 
 
Lung Cancer: US$1,361,355 
 
Male 
Number of cases =214, cost per case=5,393, and SAF=0.9, therefore 




Number of cases =193, cost per case=5,393, and SAF=0.31, therefore 




Male 30 to 45 years old 
Number of cases =407, cost per case=5,650, and SAF=0.39, therefore 
The cost of treatment of stroke attributable to smoking for male 30 to 45 years old 
=407*5,650*0.39=US$896,825 
 
Male 46+ years old 
Number of cases =1425, cost per case=5,650, and SAF=0.485, therefore 
The cost of treatment of stroke attributable to smoking for male aged 46+ years old 
=1425*5,650*0.485=US$3,904,856 
 
Female 30 to 45 years old 
Number of cases =534, cost per case=5,650, and SAF=0.044, therefore 
The cost of treatment of stroke attributable to smoking tobacco for female aged 30 to 45 years 
old=534*5,650*0.044=US$132,752 
 
Female 46+ years old 
Number of cases =1,386, cost per case=5,650, and SAF=0.123, therefore 







Number of cases =986, cost per case=1,661, and SAF=0.813, therefore 




Number of cases =878, cost per case=1,661, and SAF=0.306, therefore 





Number of case=12,896, cost per case=2,743.5, and SAF=0.1394 therefore 
The cost of TB treatment attributable to smoking tobacco= 12,896*2,743.5*0.1394 
=US$4,931,996.53 
 
Table 7: Total variable health care costs attributable to smoking in Cambodia in 2013 
Diseases Attributable cost (USD) 
Ischemic Heart Diseases $1,658,608 






Adding the smoking attributable costs of treatment for the all five health conditions (Lung 
Cancer, IHD, Stroke, COPD and TB) generates the total of US$15,627,339. This amount 
represents the variable cost of treating smoking-attributable diseases in Cambodia in year 2013. 
Step 4: Estimating the full cost of treatment by taking into account the depreciation and the fixed costs 
Total full treatment cost = the treatment cost /45.3*100 
= US$15,627,339/45.3*100 
=US$ 34,497,437 
This means that the total health care costs in Cambodia that can be attributable to smoking 
based on the five diagnoses included in this study is US$ 34,497,437. 
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Phase 2: Estimating Productivity Loss 
The productivity loss (also called indirect costs) consists of costs related to premature mortality 
and morbidity caused by smoking. 
Step 1: Estimating productivity cost of  premature mortality 
 
The current smoker loses on average 12 years of life and there are 10,000 deaths per year in 
Cambodia. The GDP per capita is 1,007 USD.  Therefore,  
Mortality productivity cost = (12*10,000)*1,007= US$120,840,000  
Step 2: Estimating productivity cost due to morbidity 
Lung Cancer 
 
Lung Cancer for male 
A patient and a caregiver spent 10 days in a hospital and 10 months at home. We assumed 20 
workdays per month. There were 214 cases of lung cancer for male in 2013 and SAF of Lung 
Cancer for male is 0.90.  Therefore 
 
The mortality-related cost for Lung Cancer of male=7*210*2*214*0.90= US$566,244 
 
Lung Cancer for female 
A patient and a caregiver spent 10 days in a hospital and 10 months at home. We assumed 20 
workdays per month.  There were 193 cases of lung cancer for female in 2013 and the SAF of 
Lung Cancer for female is 0.31.  Therefore 
 
The mortality-related cost for Lung Cancer of female=7*210*2*193*0.31= US$175,900.20 
 
Total mortality-related cost of LUNG CANCER=US$742,144.20 
IHD 
 
IHD for male age 30-45 years old 
A patient and a caregiver spent on average 8 days in a hospital and 10 days at home. There were 
117 cases of male age 30-45 years old for IHD in 2013 and the SAF of IHD for male age 30-45 
years old is 0.667.  Therefore 
 
The mortality-related costs for IHD of male age 30-45 years old 
=7*18*2*117*0.667=US$19,665.83 
 
IHD for male age 46-59 years old 
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A patient and a caregiver spent on average 8 days in a hospital and 10 days at home. There were 
247 cases of male age 46-59 years old for IHD in 2013 and the SAF of IHD for male age 46-59 
years old is 0.475.  Therefore 
 
The mortality-related costs for IHD of male age 46-59 years old 
=7*18*2*247*0.475=US$29,565.90 
 
IHD for female age 30-45 years old 
A patient and a caregiver spent on average 8 days in a hospital and 10 days at home. There were 
146 cases of female age 30-45 years old for IHD in 2013 and the SAF of IHD for female age 30-45 
years old is 0.047.  Therefore 
 
The mortality-related costs for IHD of female age 30-45 years old 
=7*18*2*146*0.047=US$1,729.22 
 
IHD for female age 46-59 years old 
A patient and a caregiver spent on average 8 days in a hospital and 10 days at home. There were 
268 cases of female age 46-59 years old for IHD in 2013 and the SAF of IHD for female age 46-59 
years old is 0.098.  Therefore 
 
The mortality-related costs for IHD of female age 46-59 years old 
=7*18*2*268*0.098=US$6,618.53 
 
Total mortality-related cost of IHD=US$57,579.48 
Stroke 
Stroke for male age 30-45 years old 
 
A patient and a caregiver spent the total of 240 days in a hospital and recovering at home until 
they could resume work.  There were 407 cases of stroke for male age 30-45 years old in 2013 
and the SAF of Stroke for male age 30-45 years old is 0.39.  Therefore 
 
The mortality-related cost of Stroke for male age 30-45 years old =7*240*2*407*0.39= 
US$533,332.80 
Stroke for male age 46-59 years old 
 
A patient and a caregiver spent the total of 240 days in a hospital and recovering at home until 
they could resume work.  There were 1,425 cases of stroke for male age 46-59 years old in 2013 
and the SAF of Stroke for male age 46-59 years old is 0.485.  Therefore 
 




Stroke for female age 30-45 years old 
 
A patient and a caregiver spent the total of 240 days in a hospital and recovering at home until 
they could resume work.  There were 534 cases of stroke female age 30-45 years old in 2013 
and the SAF of Stroke for female age 30-45 years old is 0.044.  Therefore 
 
The mortality-related cost of Stroke for female age 30-45 years old =7*240*2*534*0.044= 
US$78,946.56 
Stroke for female age 46-59 years old 
 
A patient and a caregiver spent the total of 240 days in a hospital and recovering at home until 
they could resume work.  There were 1,386 cases of stroke for female age 46-59 years old in 
2013 and the SAF of Stroke for female age 46-59 years old is 0.123.  Therefore 
 
The mortality-related cost of stroke for female age 46-59 years old =7*240*2*1386*0.123= 
US$572,806.08 
Total mortality-related cost of STROKE=US$3,507,265.44 
COPD 
COPD for male 
A patient and a caregiver spent 10 days in a hospital and 20 days at home.  There were 986 
cases of COPD for male in 2013 and the SAF of COPD for male is 0.813.  Therefore 
The mortality-related cost of COPD for male =7*30*2*986*0.813=US$336,679.56 
COPD for female 
A patient and a caregiver spent 10 days in a hospital and 20 days at home.  There were 878 
cases of COPD for female in 2013 and the SAF of COPD for female is 0.306.  Therefore 
The mortality-related cost of COPD for female =7*30*2*878*0.306=US$112,840.56 
Total mortality-related cost of COPD=US$449,520.12 
TB 
A patient and a caregiver spent 105 days in hospital and at home.  There were 12,896 cases of 
TB in 2013 and the SAF of TB is 0.1394.  Therefore 
The mortality-related cost =7*105*2*12,896*0.1394=US$2,642,622.53 
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Table 8: Productivity costs of smoking related morbidity 
Diseases Costs (USD) 
IHD  $               57,579.48 
Lung Cancer  $             742,144.20 
Stroke  $          3,507,265.44 
COPD  $             449,520.12 
TB  $          2,642,622.53 
Sub-total  $          7,399,131.77 
 
Sum up the estimation Productivity Loss (Cost) 
 
The total productivity loss for five diseases (IHD+ Lung Cancer+ stroke+ COPD+TB) in 2013 was 
US$120,840,000+US$7,399,131.77=US$128,239,131.77 
 
Sum up the estimation of the total society costs attributable to smoking 
 
The total society costs attributable to smoking including the health care costs and productivity 
loss are US$ 162,736,568.77, which equal to 1.05% of Cambodia’s 2013 GDP26. (Table 8) 
Table 9: Estimation of the total costs attributable to smoking tobacco 
Description Cost  (USD) 
Total cost of treatments  $                            34,497,437.00  
Total productivity cost   $                            128,239,131.77 
Total costs of smoking  $                            162,736,568.77 
 
Phase 3: Case Studies  
Eight case studies were important part of the methodology, because they provided data on the 
number of days lost from work due to a specific illness and confirmed that people are seeking 
medical help outside the system of government hospitals.  We interviewed three patients with 
IHD, two stroke patients, two COPD patients and one lung cancer patient.  
This section describes the health seeking behavior of patients who suffer from tobacco related 
diseases, their health care cost related to the diagnosis, treatment and rehabilitation as well as 
their smoking history. 
26 http://data.worldbank.org/indicator/NY.GDP.MKTP.CD  retrieved on 28 December 2015 
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Health seeking behavior of patients  
Health seeking behavior may vary according to the socio-economic status of the family.  Based 
on secondary data, by 2010, only 29% of patients sought care first in the public sector and 57% 
with private providers27, which was consistent to the findings of qualitative study which was 
found that once experiencing disease symptoms, the patients usually buy over-the counter 
medicines or see a private doctor as the first step.  When the symptoms become severe/life 
threatening, patients usually go to a national hospital operated by the government or to a 
private hospital.  In some cases, the patients are not confident in the ability of local hospitals to 
handle their case and seek a second opinion and/or treatment abroad, most commonly in 
Thailand or in Vietnam.  If diagnosed abroad, they either proceed with a treatment abroad or 
bring the diagnoses obtained abroad to Cambodia where they continue treatment in a local 
facility (either public or private) and purchase their mediations out of pocket.  The majority of 
these choices are driven by available resources with the diagnoses/treatment abroad being the 
most expensive, followed by a private facility in Cambodia.  A national hospital is still the 
cheapest option, but many patients struggle to pay for the care even in these facilities 28,29. 
 
27 Peter Leslie Annear, Health Sector Analysis, Ministry of Health, Cambodia, 2014 
28 Cambodia Annual Health Financing report 2014 
29 Tracking Universal Health Coverage report, WHO, 2014 
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Case Study 1: A stroke  
Sophal, 52, married man, was an engineer working for the government, but also running his 
private business supervising construction sites.  Sophal has been a heavy smoker for more than 
20 years. He used to smoke one to two packs a day. He also drinks alcohol. 
Before he got ill, he made approximately US$ 3,000 per month, this is a very high income 
according to Cambodia standard, where minimum wage is approximately US$ 150 per month. 
This income comes from his government salary at US$ 200 per month and his private work.  In 
May 2015, Sophal started to feel dizzy, experienced headaches, tension in his head, neck and 
chest. He was admitted to Calmette hospital and was diagnosed with a stroke.  His family 
decided in the same day to take him to Vietnam for further diagnosis and treatment.  They 
travel to Vietnam in a private car and was hospitalized in a private hospital in Ho Chi Minh city 
for 14 days.  After that he stayed in Vietnam for one more month for a follow-up.  Upon his 
Buying over the counter 
medicine or seeing private 
doctor (n=2) 
Seeking diagnosis at national 
hospital (n= 7) or private 
hospital (n=1) 
Treatment at a national or a 
private hospital n=5 
Treatment abroad 
(Thailand or Vietnam) n=3 
Follow up in Cambodia (a 
national or a private hospital) 
n=8 
Having symptoms for a 
while before falling sick 
Suddenly feeling sick 





return to Cambodia, he continued his follow-up at Calmette hospital.  He had to visit Calmette 
hospital 3 times per week for rehabilitation (learning to walk and speak).  He also needed to 
additional physiotherapy twice a day until presence (for 6 months until interview day).  Sophal 
took medicines to speed up his recovery.  Sophal and his family spent US$ 15,288 for the 
diagnosis, hospitalization, and treatment from the time he had stroke until 5 months after the 
event.  His condition improved significantly, although his right hand and leg remained paralyzed.  
He could barely walk without help, and he could not speak.  The doctors expected that he will be 
able to speak and walk in about a year that is within 1.5 years after the incident.  
His wife is his main caregiver accompanying him to all his hospital visits while she struggles to 
take care of the rest of the family., 
The disease affected Sophal's family both economically and socially.  The family used its savings 
to pay for the diagnosis and treatment.  They are very concerned that Sophal will not be able to 
resume his work and earn regular income that the family depends on.  This could push the 
family into the poverty.  There are no particular benefits for sick person like Sophal, he 
continues to receive his monthly government salary although he is sick, but he does not have 
income from his private work, thus putting his family into a hard time to cover his treatment. 
Before his illness, Sophal has never tried to quit smoking and was never concerned about the 
health damage smoking could cost.  He quits smoking after he was diagnosed and informed that 
his illness was caused by smoking.  
The case of Sophal demonstrates a typical health care seeking behavior among those relatively 
well off. Sophal was able to go to multiple health care providers.  It is not uncommon that 
Cambodians seek health care abroad, especially in Vietnam due to lack of trust on the quality of 
health care provided by public hospital. 
 
Case Study 2: COPD 
Sokha, a married man, age 65, lives in Sihanouk Province, the coastal areas in the southwest of 
the country at the Gulf of Thailand.  He is a farmer.  His wife is a grocery seller. The family has 
only a modest income and supported by his brother who is an owner of the farm that he is 
working for. Sokha has four children who work in private sector. 
Sokha has been a heavy smoker for more than 30 years consuming at least 2 cigarette packs per 
day. 
Sokha had hypertension and has been coughing for about 10 years before he experienced 
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difficult breathing in December 2014 and was referred to Khmer-Russian hospital in Phnom 
Penh. He was diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and admitted to 
the hospital for 18 days.  At that time, he decided to quit smoking.  Four months later after his 
discharge (Jan 2015), in April 2015 he got a flu, had difficulty breathing and even lost his 
conscious.  He was admitted to the same hospital for the second time, this time he was 
hospitalized for 14 days.  Following this hospitalization, he had to take prescribe medicines for 
one month that cost him US$ 120.  After that he needed to return to the hospital every month 
for a follow-up for the first six month and had to continue using his medicines that cost him US$ 
120 per month.  Overall, his family spent close to US$ 13,000 over the course of two years to 
treat his illness.  He used up all his savings and received support from his brother and children to 
cover the costs.  
The case of Sokha demonstrates that the drain on family resources does not stop after the 
diagnoses and hospital treatment. Sokha's condition requires continued treatment with 
significant monthly expenses.  
He continues to work at the farm owned by his brother, but he can only do light work and 
requires more rest.  His wife always accompany him while he is sick at hospital or at home, she 
had to close her grocery story to help with the family farm since the productivity of her husband 
declined.  
 
Case Study 3: Lung Cancer 
Saroeun, age 51, married with three children and lives in Phnom Penh.  Sarouen has been a 
heavy smoker.  He began smoking when he was ten years old.  He recalls smoking more during 
Pol Pot regime (1975-1979).  As a teenager, he used to smoke hand-rolled cigarette consuming 
about half kilogram of dry tobacco leaf in a week.  After the regime change in 1979, Saroeun 
smoked variety of brands, about two packs a day for about 20 years.  Sarouen never thought 
that smoking could make him sick.  He has heard about the harm of smoking and his wife and his 
children asked him to stop, but he never tried to quit. 
Before he got sick, Saroeun was a police officer with a modest salary of about US$ 200 per 
month, which was supplemented by other income [they declines to report the source and 
amount of extra income]. 
Saroeun first felt sick in March 2014, when he started to cough blood.  He sought treatment 
from a nearby pharmacy, because he thought that it was a severe flu.  The bleeding did not stop 
and he went to Calmette hospital to diagnose the problem.  The hospital did a CT scan and a 
biopsy of his lungs after a doctor found a tumor in his right lung. When the results of the biopsy 
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returned back from a lab in France, the doctor confirmed lung cancer. 
Saroeun and his family were shocked.  Saroeun has never been diagnosed with any health 
problems in the past.  Saroeun and his family went to Bangkok to confirm the diagnosis and to 
begin treatment.  At that point, Saroeun stopped smoking.  The PhyaThai hospital in Bangkok 
confirmed stage 3 lung cancer and the local doctor suggested a surgery. Saroeun and his family 
refused the surgery and begin chemotherapy in the hospital.  Saroeun stayed in the PhyaThai 
hospital for 20 days and spent about US$ 10,000 for the treatment. Running out of savings, 
Saroeun and his family requested to be discharged from the PayaThai hospital to the Rama 
government hospital where the treatment was cheaper.  At Rama, Saroeun underwent 23 
chemotherapy sessions. He stayed in Bangkok to get his first six chemotherapy sessions.  Then 
he returned to Cambodia and travelled back and forth between Bangkok and Phnom Penh to 
receive the remaining treatment.  At that point, the family has spent about US$ 90,000 for his 
treatment, travel and four months stay in Bangkok.  At the end, the family decided to stop 
treatment in Thailand, because it could not afford it and Saroeun was not getting any better. 
Saroeun continues his treatment at Calmette hospital in Phnom Penh. 
Saroeun spent at least 10 months in treatment.  He stopped working completely, and his wife 
estimates that the couple spent approximately US$ 120,000 during these 10-months to cover 
the cost of treatment, travel, and their stay in Bangkok.  So far, his wife said that she spent all 
her saving and sold jewelry to cover these costs. 
 
Case Study 4: Ischemic Heart Disease (IHD)  
Mr. Piseth, age 53, married with two children, is agriculture professional.  He has been a heavy 
smoker for approximately ten years. Until May 2015 he has been a healthy man.  In May he 
experienced a severe chest pain that did not respond to painkillers and his blood pressure 
skyrocketed. 
His wife took him to a private hospital in Phnom Penh where a doctor found that his three 
coronary vessels were blocked.  He was diagnosed with ischemic heart disease (IHD) and needed 
a surgery. He stopped smoking immediately.  His one night stay at the private hospital that 
diagnosed his illness cost him US$ 800.  The next day he flew to Bangkok with his wife for the 
surgery that cost US$ 20,000.  Following the surgery in Bangkok he was hospitalized for seven 
days and then stayed in Bangkok for one more week after the hospitalization for the follow-up 
treatment.  He and his wife stayed at a hotel and went to the hospital every day.  Upon his 
return to Phnom Penh, he has to recover at home for one month, after which he resumed to 
work.  But only part time, because he was still weak to work full time. 
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Piseth continues to take daily medication that cost around US$ 80-100 per month. He also needs 
to go to Bangkok every 6 months for a follow-up that costs US$ 1,500. 
So far, the family spent approximately US$ 26,765, but this is not the final bill, since the 
medication needs to be taken and future follow-ups in Bangkok.  
His wife was his main caregiver.  She is a government officer and she missed many days from 
work during Piseth's hospitalization in Bangkok and during the follow-up treatment. 
Health care cost 
As discussed earlier the health care costs vary according to the capacity of a particular health 
care facility to treat certain health condition, but also by the ability of a patient to pay for the 
treatment.  The health care costs in the Sophal's case (stroke) were mostly related to the 
hospital treatments, medications and transportation.  
The costs reported by the lung cancer patient were much higher compared to those provided by 
the hospital experts, most likely due to some health care being provided in Thailand.  The lung 
cancer diagnoses and treatment costs approximately US$ 5,393 in a national hospital, but 
Saroeun, the lung cancer patient paid approximately US$ 120,000 for his treatment abroad and 
in the country. 
Similarly, the health care costs associated with other conditions were determined by the type 
and variety of health providers. For example, Piseth and his family spent US$ 26,765 for the 
treatment of his IHD (including a surgery) in Thailand.  This cost was about triple the amount of  
US$ 7,259 estimated by a Cambodia government hospital (Calmette) inclusive of a surgery).  On 
the other hand, Samnang who also suffered from IHD, spent approximately US$ 6,600 for his 
diagnosis and treatment that did not required a surgery.  However, in case of Samnang, some 
costs (e.g. materials and equipment) were covered by humanitarian aid to Cambodia, because 
he was treated in a non-for-profit hospital that charges lower fees to the patient with financial 
difficulty.   
Smoking Behavior of Patients Participating in the Case Studies 
All case study participants were heavy smokers for more than ten years before their diagnoses. 
None of them considered smoking to be a health risks and they never tried to quit.  After 
learning that their sickness is related to tobacco use, they all quit smoking and regretted that 
they have smoked. 
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I really regretted that I have been smoking for so many years. My wife and my children 
advised me to quit but I did not listen. Now I want to quit for good and I can do it, it just 
needs a commitment (Bunthan, 49, IHD) 
 
Discussions 
In this study we estimated the cost of smoking in Cambodia that is related to health care and the 
loss of productivity due to poor health.  
The study applied relative risks (RRs) from CPS-II to calculate SAFs of health care costs.  Similar 
approach has been previously applied in Vietnam and in other countries in the region.  It has 
been argued that RRs from CPS-II provided the higher bound due to estimates based on Chinese 
data suggesting that the RRs could be lower. However, a recent study confirmed that using CPS-
II as the base for RRs in Asia seems appropriate (Pham Thi, et al, 2014).  
Though the cost per case of the five diseases is well estimated, we believe that the estimated 
total costs of smoking presented in this study represent the lower bound of these estimates due 
to the following factors: 
- The study considered only five major health conditions, but there are as many as 40 
diseases related to smoking.  Furthermore, the study does not include the costs related 
to passive smoking, the costs related to fires caused by smoking, and cost of buying 
cigarettes among Cambodia tobacco user aged over than 15 years which was estimated 
to reach US$ 201,534,701 in year 201430. 
- We relied on the number of cases per diseases from the national hospitals' records, 
which actually was lower than the reality. According Peter Annear, 2014, the use of 
public health facilities for hospitalisation reaches 60% of health service users, the use of 
public facilities for primary care remains low (apart from maternal and child health)31.  
However, we know thanks to our case studies and discussions with medical 
professionals during the course of the study that not all cases end up in the national 
hospitals.  In recent years, the number of patients seeking health care from private 
facilities and/or in abroad has increased significantly.  In addition, many patients do not 
go to national hospitals for treatment, because they cannot afford it32.  
- The costs presented in the study reflect hospital costs.  Therefore it does not cover 
outpatient care and/or self-treatment.  This further contributes to the underestimation 
30 National Adult Tobacco Survey of Cambodia, National Institute of Statistics, Ministry of Planning, 2014 
31 Peter Leslie Annear, Health Sector Analysis, Ministry of Health, Cambodia, 2014 
32 MoH’s Annual Health Financing report 2015 
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of the total costs. According to study in Vietnam in 2012 the outpatient cost is 8.5% of 
total cost (smoking-attributable healthcare costs plus smoking attributable costs of 
mortality, and productivity lost due to morbidity for five smoking related diseases)4.  
This means that this cost should be under estimated by 8.5%. 
- It was not possible to estimate the depreciation and the recurrent costs of hospital 
treatment due to the lack of data kept by the hospitals.  In order to solve this problem, 
we assumed that these costs represent a similar percentage of the total costs (54.7%) as 
in Vietnam that has a similar health care system.   
The study did not employ smoking-attributable DALYs to estimate the impact of smoking related 
mortality due to the fact that these estimates have been criticized due to their upward bias, 
which is particularly pronounced in countries with relatively low life expectancy such Cambodia. 
An alternative approach employed in this study involved an estimate of the annual number of 
deaths attributable to smoking and the average number of life-years lost per smoker estimated 
by WHO.  We estimated the productivity by the GDP per capita and assumed that the annual 
GDP growth is equal the depreciation rate.  The average GDP Annual Growth Rate in Cambodia 
averaged 7.68 percent from 1994 until 201433. 
Despite these limitations, we found that smoking cost Cambodia at lease US$ 162,736,568.77 or 
about 1.05% of Cambodia’s 2013 GDP34.  This estimate is comparable to estimates in other 
countries. For example, the costs of smoking in Vietnam in 2012 accounted for 1.17% of its 
GDP35, 1.40% of 2005 GDP in the US, and 0.7% of 2008 GDP in China36. 
In regard to cost of treatments of the diseases born by smoking, in Cambodia, the cost of 
treatment financed by three sources, government, donors and household out of pocket 
spending. Total Health Expenditure (THE) has substantially increased over the last five years, 
from US$ 564 Million in 2008 to US$ 763 Million in 2012, representing more than 5% of the 
GDP. In 2012, THE was approximately US$ 52 per capita, 24% of which comes from government 
spending, 15% from development partners, and the remaining 61% from out-of pocket spending 
(OOP) 37.  Household health expenditure, via OOP, contributes the greatest part of the THE. 
Since 2008, OOP has increased from US$ 25 per capita in 2008 to US$ 32 per capita in 2012 or 
approximately US$ 459 billion, accounting for 61% of THE.   According to MoH’s Annual Health 
Financing report, 2012, the poor spend a higher share of their income than the non-poor to 
obtain the same treatment. 
 
33 http://www.tradingeconomics.com/cambodia/gdp-growth-annual retrieved on 11 January 2016 
34 World Bank, Cambodia’s 2013 GDP was US$15.23 billion 
35 Hoang Anh et all, 2012 Health care cost attributed to smoking in Vietnam, 2012 
36 Lian Yang et all. Economic cost attributable to smoking in China: update and an 8-year comparison, 
2000-2008. Tobacco Control 2011;20:266-272 
37 MoH’s Annual Health Financing report 2012 
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Limitations 
 
The study adapted the theoretical and conceptual framework employed in similar studies in 
other countries while facing some of the similar limitations.  Only five of the known diseases to 
be caused by smoking were studied.  Furthermore, morbidity associated with these diseases was 
probably underestimated; morbidity and mortality estimates did not include those for cigar 
smokers, passive smokers, pregnant women, and children; and minimum wage of garment 
factory was used to estimate productivity losses.  
Due to the lack of data, we had to adjust our original plan to employ collected primary data 
directly from hospitals that have capacity to treat the four tobacco related diseases; the study 
faced some challenges:  First, we were not able to include the costs of health care that some 
patients are obtaining abroad, and we do not know how many patients are seeking such 
treatment.  
Second, the research team did not know how many patients did not seek a treatment in a health 
care facility due to the lack of their resources to cover the costs.  As result, the number of cases 
in this study is likely to be a conservative estimate.  In addition, data in this study captured only 
officially hospital fees, but did not include other fees paid by the patients such as the costs of 
medicines purchased outside the medical facility, transport, and food for the patients and 
caregivers during hospitalization.  However, our case studies captured a broad array of costs 
incurred by the patients and their families. 
We assume that the cost of treatment for smokers and non-smokers is identical.  To the extent 
that the cost of treating a smoker is higher compared to a non-smoker due to the complications 
among smoking patients, we have underestimated the health care costs of smoking. 
 
Conclusions and recommendations 
This is the first study in Cambodia to estimate the costs of smoking.  The results show that 
smoking imposes an enormous financial burden on Cambodia society in particular among the  
poor.  The total costs of smoking related to the health care reached US$ 34,497,437 while the 
productivity loss amounted to US$ 128,239,131,77in 2013.  The total costs of health damage 
reached US$ 162,736,568.77, which represents 1.05% of Cambodia’s 2013 GDP. 
Despite the study limitations, these estimates are useful for decision-makers and tobacco 




It is necessary to strengthen the health information system (HIS) under the leadership of the 
Department of Planning and Health Information System of the Cambodian Ministry of Health. 
The current system does not allow disintegrating information for the purpose of assessing the 
burden of Non Communicable Diseases at different levels of care (national, regional, provincial).  
An improvement in data collection and data management will allow calculating more refined 
estimates of the costs of smoking in the future. 
The cost for treating tobacco related diseases and productivity loss due to active smoking was 
nearly 12 times higher than the total domestic tobacco tax revenue (US$ 13, 825,230 million) 
collected by General Department of Taxation in 201338.  
Raising awareness among policy makers about this significant negative impact of smoking on 
Cambodia economy will be critical to ensure the adoption of stronger tobacco control policies in 
Cambodia.  Raising awareness among the general population about the burden that tobacco use 
poses on their household financial security is also necessary to gain support on tobacco control 
program. Raising excise tobacco taxes has been proven to be the win-win approach to reduce 
tobacco consumption while raising government tax revenue.  Currently tobacco tax in Cambodia 
remains low at around 19-26% of the retail price while WHO recommended that this rate should 
be from 66%-80% of the retail price. 
38 WHO’s Global Report on Tobacco, 2015 
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Annex 1: Survey of costs for a standard diagnosis, the treatment and a 
follow up 
 
The missing data in the table below means that the procedure is not performed in the relevant 
hospitals.  It is evident, that the public hospitals offer more health care services compared to 
private hospitals.  This is because private hospitals often refer a patient to a public hospital if the 
case is severe or if the patient cannot cover the costs of private health care. In case of Royal 
Ratanak hospital, a patient who can afford it is transferred to a Bangkok hospital in Thailand.  
 
The figures in all tables refer to cost of the procedure indicated in the first column in different 
hospital (10 hospitals). The amount of money is in US$  
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Annex 2: Interview guide for case studies with patients suffered from 
tobacco related diseases 
 
Objective: 
To learn a pattern of health seeking behaviour that patients and family have undergone to seek 
care to treat tobacco related diseases and cost associated to treatment and other indirect costs. 
As patients in Cambodia usually seek care from private providers (in some cases outside the 
countries) the case studies will provide full picture of all treatment/services patients has sought 
care from and cost associated to that. 
 
Interview guide 
Themes Main questions Probe 
Socio-demographic 
characteristics 
1. What is your name?  
2. Sex? 
3. Age? 
4. What is your marital 
status? 
5. How many children do you 
have? 
6. What is your main job? 
7. What is your spouse main 
job? 
8. Your income per month? 
9. How is income of your 
family? 







Pattern of health seeking 
behaviour that patients and 
family have undergone to 
seek care to treat tobacco 
related diseases and cost 
associated to treatment 
and other indirect costs 
11. What is your health 
problem (Lung cancer, 
COPD, IHD, Stroke)? 
12. What are the first 
symptoms/sign you 
experiences? 
13. How long (years/months) 
have you encounter this 
health condition (disease)?  
14. How did you know that 
health condition (disease)? 
or who tell you about your 
disease? OR Where did you 
get diagnosed with that 
particular disease? 
15. What cost associated with 
the diagnosis? 
16. From the first time you got 
this symptom/sign, what 
did you do to relieve this 
health condition 
(symptom, or disease)? 
17. What is cost associated 
with your care seeking 
before being diagnosed?  
 
18. Later on, how did you try to 
treat this health condition?  
It is by your-self (buy 
medicine, take traditional 
herb, etc)? or seeking to 
consult with other people 
like traditional healers, local 
private health 
professionals, or public 
health facility in your 
community? public health 
facility far from your home 
(district, province, Phnom 
Penh capital city, abroad 
like in Vietnam/Thailand, 
etc)?  
19. How often or how long did 
you try to treat your-self or 
try to use traditional 
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medicine before experience 
with modern medicine? 
20. How often or how long did 
you were admitted to 
hospital for treating your 
disease after diagnosed? 
21. And which hospitals?  
Please mention? 
22. Do you currently have pain? 
23. During staying in hospital, 
who were your care givers 
(wife, children, friends, 
relative)? 
24. Who were the full time care 
givers? And who were the 
part time care givers? 
25. How is this affect on your 
job and income?  
26. How long have you lost 
your job? 
27. How are your care giver job 
and income? Did any care 
givers lost job? And how 
long? 
28. How is the economic status 
of your family after you 
suffer from this health 
condition? 
29. How is the feeling of your 
family toward you? 
30. Did you have stigma and 
discrimination from your 
family members (wife, 
children, parent) and 
friends in regard to your 
chronic and serious health 
problem?  If yes, to what 
extent is the stigma and 
discrimination are? 
31. How do you feel about 
your own health 
condition? 
32. How do you feel (concern) 
about the future of your 
family? 
 33. Do you still smoke during 34. If yes, how long have you 
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Smoking behaviour  last 30 day? smoke? and how many 
cigarette do you usually 
smoke per day? 
35. Do you smoke hand roll 
cigarettes or manufacture 
cigarettes 
 36. If no, did you smoke in the 
past? And how long have 
you smoke before the day 
you quit? and how many 
cigarette did you usually 
smoke per day? 
37. Did you smoke hand roll 
cigarettes or manufacture 
cigarettes 
38. How long have you quit 
smoking? 
39. Do you have any words to 
say for the smokers? 
40. Are you happy with the 
quality of care you have 
received so far? What 
would you change? What 
improvements can be 
made? 
 
Thanks you very much for your kind participation!! 
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